This story was originally published April 14.

Agilent Technologies said last week that large-scale Chinese genome center BGI will use several of its products as part of its next-generation sequencing process.

Specifically, BGI will use Agilent's SureSelect solution-based target enrichment product for targeted sequencing in human genetic studies, particularly in cancer genome projects.
BGI researchers worked with Agilent's China Life Science group and Agilent R&D to test and validate SureSelect.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.